hormoneNot FDA-approvedResearch chemicalNo phase 3 program has been publishedProhibited in sport by WADA
LigandrolBenefits, Dosage & Interactions
Also known as: LGD-4033, Anabolicum
Ligandrol, also known as LGD-4033 or Anabolicum, is a synthetic, non-steroidal selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar anabolic properties to anabolic steroids but with reduced androgenic (masculinizing) properties. Research on Ligandrol focuses on muscle and strength, bone and joint health, and testosterone support.
How much Ligandrol do people take?
0.1 mg, 0.3 mg and 1.0 mg daily arms in the single published healthy-volunteer study. Route reported: Oral. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Ligandrol — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Moderate — One published human randomized trial; results not yet replicated.
Evidence strengthModerate · 3/4
PreclinicalStrong human evidence
One published human randomized trial; results not yet replicated.
Plasma half-life
24–36 h
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
- Reported amounts
- 0.1 mg, 0.3 mg and 1.0 mg daily arms in the single published healthy-volunteer study[1]
- Route studied
- Oral[1]
- Frequency
- Once daily[1]
- Cycle length
- 3 weeks in that study[1]
- Half-life
- 24-36 hours as reported in the phase 1 pharmacokinetics[1]
- Storage
- Room temperature, dry[1]
Reported for Ligandrol in the cited sources. Published ranges are not dosing advice.
Ligandrol compared with similar compounds
| Attribute | Ostarine (enobosarm) | Ligandrol (LGD-4033) | Testolone (RAD-140) | Cardarine (GW501516) |
|---|---|---|---|---|
| Class | Nonsteroidal SARM | Nonsteroidal SARM | Nonsteroidal SARM | PPAR-delta agonist (not a SARM) |
| Route | Oral | Oral | Oral | Oral |
| Half-life | ~24 hours | 24-36 hours | Not established in humans | Not established in humans |
| Evidence grade | Moderate | Limited | Preclinical | Preclinical |
| Oral stability | Orally active | Orally active | Orally active | Orally active |
| Typical published cycle | 12-16 weeks in the published phase 2 trials | 3 weeks in the only published healthy-volunteer trial | No published human dosing trial | No published human dosing trial |
| Main studied use | Muscle wasting in cancer (investigational) | Lean mass in healthy young men (phase 1) | Androgen receptor signaling (preclinical) | Endurance and lipid metabolism (animal work) |
References & evidence
Documents the Ligandrol entry is written from. Each number matches an inline marker above.
- [1]The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young menBasaria S, Collins L, Dillon EL, et al. · The Journals of Gerontology: Series A · 2013 · Peer-reviewed · PMID 22459616
- [2]Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trialDobs AS, Boccia RV, Croot CC, et al. · The Lancet Oncology · 2013 · Peer-reviewed · PMID 23499390
References & Evidence
Sources on this page that document Ligandrol dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is Ligandrol studied for?
What is Ligandrol?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
Ligandrol, also known as LGD-4033 or Anabolicum, is a synthetic, non-steroidal selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar anabolic properties to anabolic steroids but with reduced androgenic (masculinizing) properties. Ligandrol was developed by Ligand Pharmaceuticals and is currently being investigated for its potential in treating conditions such as muscle wasting and osteoporosis. (PubChem)
Unlike traditional anabolic steroids, which bind to androgen receptors throughout the body, SARMs like Ligandrol are designed to selectively bind to androgen receptors primarily in muscle and bone tissue. This selectivity aims to minimize unwanted side effects commonly associated with anabolic steroids, such as prostate enlargement, acne, hair loss, and liver toxicity. (DrugBank)
Despite its potential therapeutic applications, Ligandrol has gained popularity in athletic and bodybuilding communities as a performance-enhancing drug due to its purported ability to increase muscle mass and strength. However, it is not approved for human use by regulatory bodies like the U.S. Food and Drug Administration (FDA) for any medical condition, and its use in sports is prohibited by organizations such as the World Anti-Doping Agency (WADA). (FDA, WADA website)
Research on Ligandrol is ongoing, with studies exploring its efficacy and safety profile. Early clinical trials have shown promising results in increasing lean body mass and muscle strength in healthy men. However, long-term safety data and a complete understanding of its side effects are still under investigation. (PubChem)
What does the research say about Ligandrol?
Tap a section to expand.
Ligandrol (LGD-4033) exerts its effects by acting as a selective androgen receptor modulator (SARM). This means it binds to androgen receptors in a tissue-selective manner. Androgen receptors are a type of nuclear receptor found in cells that, when activated, regulate the expression of genes involved in the development and maintenance of male characteristics, including muscle growth and bone density. (DrugBank)
The selectivity of Ligandrol is crucial to its proposed therapeutic advantage. While traditional anabolic steroids activate androgen receptors broadly across various tissues, leading to systemic effects, Ligandrol is designed to primarily activate androgen receptors in skeletal muscle and bone tissue. This selective activation is intended to promote anabolic effects (muscle growth, increased bone mineral density) while minimizing androgenic side effects in other tissues, such as the prostate gland, sebaceous glands (which can cause acne), and hair follicles. (PubChem)
When Ligandrol binds to androgen receptors in muscle cells, it triggers a cascade of events that ultimately leads to increased protein synthesis and muscle hypertrophy (growth). In bone tissue, it can stimulate osteoblast activity, contributing to increased bone density. The exact mechanisms by which Ligandrol achieves this tissue selectivity are still being fully elucidated but are thought to involve differential co-factor recruitment in various cell types upon binding to the androgen receptor. (DrugBank)
Source for this section: Sources for How does Ligandrol work?: Jumps to this entry in the sources and references list at the end of the page.
Potential benefits of Ligandrol (LGD-4033) are primarily focused on its anabolic properties, particularly in muscle and bone. However, it's crucial to reiterate that these are potential benefits from research studies and anecdotal reports, and Ligandrol is not approved for any medical use.
* **Increased Lean Muscle Mass:** Clinical trials have investigated Ligandrol's ability to promote an increase in lean body mass. A phase 1 clinical trial found that healthy men receiving LGD-4033 experienced a dose-dependent increase in lean body mass over several weeks. This effect is attributed to its selective activation of androgen receptors in muscle tissue, leading to enhanced protein synthesis. (PubChem)
* **Increased Strength:** Along with increases in muscle mass, users and studies have reported improvements in strength. This is a common associated benefit with increased muscle size and density. (Anecdotal reports, supported by mechanism)
* **Improved Bone Mineral Density:** Early research suggests Ligandrol may have anabolic effects on bone tissue, potentially increasing bone mineral density. This makes it a candidate for research into conditions like osteoporosis, where bone strength is compromised. (DrugBank)
* **Potential for Fat Loss:** While not a primary mechanism, increased muscle mass can lead to an elevated basal metabolic rate, which can indirectly contribute to fat loss, especially when combined with diet and exercise. (General physiological principle)
It is important to understand that these benefits are from the context of research or unapproved use. The long-term safety and overall efficacy of Ligandrol are still under investigation. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Evidence regarding Ligandrol (LGD-4033) primarily stems from preclinical studies and early-phase human clinical trials. It's important to note that, as an investigational compound, its evidence base is still developing.
* **Clinical Trials:** A significant early study is a randomized, double-blind, placebo-controlled Phase 1 trial published in The Journals of Gerontology, Series A, in 2013. This study investigated the safety, pharmacokinetics, and effects of LGD-4033 in healthy men. Researchers found that LGD-4033 was well-tolerated at all doses, with no serious adverse events reported. Importantly, they observed a dose-dependent increase in lean body mass in participants, even at low doses, and a dose-dependent decrease in total testosterone, sex hormone binding globulin (SHBG), and high-density lipoprotein (HDL) cholesterol. (NIH ODS via PubChem)
* **Preclinical Studies:** Animal studies have also demonstrated the anabolic effects of LGD-4033 on muscle and bone. These studies provide foundational understanding of its mechanism of action and tissue selectivity. (DrugBank)
* **Expert Reviews and Monographs:** Organizations like PubChem and DrugBank provide comprehensive chemical and pharmacological information on LGD-4033, summarizing available research data, including its proposed mechanism, metabolism, and known effects from studies. (PubChem, DrugBank)
* **Regulatory Status:** The fact that LGD-4033 is not approved for human use by the FDA underscores that its efficacy and safety profile have not been fully established to meet regulatory standards. Its presence on the World Anti-Doping Agency (WADA) prohibited list across all sports highlights its classification as a performance-enhancing substance. (FDA, WADA website)
While early evidence suggests potential anabolic benefits, a complete understanding of Ligandrol's long-term safety, optimal dosing, and full spectrum of effects requires further comprehensive research. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
While Ligandrol (LGD-4033) is promoted as having fewer side effects than traditional anabolic steroids due to its selectivity, it is not without risks. Its full side effect profile, especially with long-term use, is not yet fully understood due to its investigational status. Common and reported side effects include:
* **Testosterone Suppression:** Clinical trials have consistently shown that Ligandrol can suppress natural testosterone production in a dose-dependent manner. This suppression can lead to symptoms such as fatigue, decreased libido, and mood changes. (PubChem)
* **Lipid Profile Changes:** Studies have indicated that Ligandrol can decrease levels of high-density lipoprotein (HDL) cholesterol (often referred to as “good” cholesterol), which could potentially impact cardiovascular health. (PubChem)
* **Hair Thinning/Loss:** Although designed to be less androgenic, some anecdotal reports suggest users may experience hair thinning or increased shedding. (Anecdotal reports)
* **Acne:** While less common than with traditional steroids, some individuals may experience acne outbreaks. (Anecdotal reports)
* **Nausea/Digestive Upset:** Gastrointestinal issues have been reported by some users. (Anecdotal reports)
* **Headaches:** Headaches are another reported symptom during use. (Anecdotal reports)
More severe but less common or unconfirmed potential side effects, often speculated based on the mechanisms of similar compounds, could include liver strain or adverse effects on other organs. However, robust clinical data for these less common effects specific to Ligandrol are still limited. Because Ligandrol is an unapproved compound, individuals considering its use do so without the full safety assurances provided by FDA-approved medications. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Due to its status as an investigational drug not approved for human use, there are significant warnings associated with Ligandrol (LGD-4033):
* **Not FDA Approved:** Ligandrol is not approved by the U.S. Food and Drug Administration (FDA) for any medical purpose. This means its safety, efficacy, and manufacturing quality have not been rigorously evaluated or guaranteed by a regulatory body. (FDA)
* **Performance-Enhancing Drug:** Ligandrol is classified as a prohibited substance by the World Anti-Doping Agency (WADA) and other sports organizations due to its anabolic properties. Athletes who use Ligandrol risk sanctions and disqualification. (WADA website)
* **Potential for Hormonal Imbalance:** Ligandrol can suppress natural testosterone production, leading to a temporary hormonal imbalance. The extent and duration of suppression, and the need for post-cycle therapy, are not fully understood or formally guided. (PubChem)
* **Lack of Long-term Safety Data:** The long-term effects of Ligandrol use on various organ systems (e.g., cardiovascular, hepatic, endocrine) are largely unknown due to limited long-term human studies. (DrugBank)
* **Product Purity and Contamination:** Because Ligandrol is sold for "research purposes only" and not as a regulated drug, products available online or in supplement stores may not contain the stated amount of LGD-4033, or they may be contaminated with other substances, including undisclosed steroids, prohormones, or other SARMs, posing unpredictable health risks. (NIH ODS)
* **Cardiovascular Risk:** Changes in lipid profiles, specifically decreases in HDL cholesterol, have been observed in clinical trials, which is a potential concern for cardiovascular health, especially with prolonged use. (PubChem)
Individuals should be aware of these significant risks before considering Ligandrol. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Due to its investigational status and lack of regulatory approval, specific medical contraindications for Ligandrol (LGD-4033) have not been fully established in the same manner as approved medications. However, based on its known pharmacological actions and potential side effects, certain individuals or conditions would be strongly advised against its use:
* **Anyone under 18 years of age:** Due to potential interference with natural hormonal development.
* **Pregnant or Breastfeeding Women:** The effects on fetal development or infants are unknown and likely harmful.
* **Individuals with pre-existing cardiovascular conditions:** Given the observed changes in lipid profiles (e.g., decreased HDL cholesterol), those with heart disease, high cholesterol, or a history of stroke should avoid Ligandrol. (PubChem)
* **Individuals with liver disease or impairment:** While direct hepatotoxicity hasn't been conclusively established for Ligandrol, many orally active compounds, especially those processed by the liver, carry a theoretical risk of liver strain or damage. (General pharmacological principle)
* **Individuals with prostate issues:** Although designed to be prostate-sparing, Ligandrol still interacts with androgen receptors. Those with benign prostatic hyperplasia (BPH) or prostate cancer may be at elevated risk.
* **Individuals with hormonal imbalances or endocrine disorders:** Given its suppressive effect on natural testosterone, individuals with pre-existing hormonal issues could experience exacerbated problems.
* **Individuals concurrently taking medications that affect hormones, lipids, or liver function:** Potential for drug interactions, increased side effects, or reduced efficacy of other medications.
As Ligandrol is not an approved therapeutic agent, these contraindications are based on general physiological principles and observed effects rather than comprehensive clinical guidelines. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Given that Ligandrol (LGD-4033) is an unapproved research chemical, specific drug-interaction studies are extremely limited or non-existent in a formal clinical setting. Therefore, a comprehensive list of compounds to avoid mixing with Ligandrol cannot be definitively provided. However, based on its known effects, theoretical interactions, and general pharmacological principles, caution should be exercised when combining Ligandrol with:
* **Other SARMs or Anabolic Steroids:** Combining multiple anabolic agents can amplify side effects, including hormonal suppression, liver strain, and cardiovascular risks, without necessarily leading to proportionally greater benefits. (General pharmacological principle)
* **Hormonal Therapies/Supplements:** Any compounds that affect the endocrine system, such as testosterone boosters, prohormones, or hormone replacement therapies, could interact unpredictably with Ligandrol's suppressive effects on natural testosterone. (PubChem)
* **Lipid-Lowering Medications:** Ligandrol has been shown to decrease HDL cholesterol. Combining it with medications that also affect lipid profiles, especially those targeting HDL, could lead to unpredictable or adverse cardiovascular effects. (PubChem)
* **Hepatotoxic Substances (alcohol, certain medications):** While specific liver toxicity for Ligandrol is not fully established, it is metabolized by the liver. Combining it with other substances known to stress the liver could increase the risk of liver damage. (General pharmacological principle)
* **Medications for Prostate Conditions:** As Ligandrol interacts with androgen receptors, mixing it with drugs for benign prostatic hyperplasia (BPH) or prostate cancer could have complex and potentially harmful interactions. (General physiological principle)
Due to the lack of formal studies, combining Ligandrol with *any* other drug, supplement, or even herbal remedy carries an unknown risk. Always err on the side of caution. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Ligandrol (LGD-4033) has a half-life of approximately 30 hours. This relatively long half-life means that it can be taken once daily to maintain stable levels in the body. The typical administration is user-directed when used outside of research settings and must be set by a licensed clinician if medically prescribed in the future.
It can be taken with or without food, as its absorption is not known to be significantly affected by meal timing. Some users prefer to take it in the morning, while others may choose to take it at another consistent time each day to establish a routine. The key is consistency to maintain steady blood concentrations. There is no evidence to suggest that specific timing of day (e.g., before exercise) provides additional benefits, given its relatively long half-life. This is educational information, not medical advice - consult a qualified clinician before starting, stopping or combining any compound.
Source for this section: Sources for When should you take Ligandrol?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about Ligandrol is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with Ligandrol?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about Ligandrol
Ligandrol, or LGD-4033, is a selective androgen receptor modulator (SARM) developed for potential treatment of muscle wasting and osteoporosis. It is designed to selectively activate androgen receptors in muscle and bone to promote growth, similar to steroids but with fewer side effects in other tissues. It is not approved for human use by the FDA. (DrugBank, FDA)
The legal status of Ligandrol is complex. It is not approved for human consumption as a drug or dietary supplement by agencies like the FDA. It is often sold as a 'research chemical.' Its use is prohibited in sports by organizations like the World Anti-Doping Agency (WADA). (FDA, WADA website)
Ligandrol is a SARM, aiming for 'selective' activation of androgen receptors primarily in muscle and bone. Anabolic steroids bind to androgen receptors throughout the body, leading to broader effects and a higher incidence of side effects like prostate issues, acne, and hair loss. Ligandrol is intended to minimize these systemic effects. (PubChem, DrugBank)
Common reported side effects include dose-dependent suppression of natural testosterone, decreases in HDL (good) cholesterol, and potentially headaches or nausea. Long-term safety data is limited, and other undisclosed side effects may exist. (PubChem)
Yes, clinical trials have shown that Ligandrol can cause a dose-dependent suppression of natural testosterone levels and sex hormone binding globulin (SHBG). This suppression can lead to symptoms associated with low testosterone after cessation of use. (PubChem)
Ligandrol is a hormone, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. With a reported plasma half-life near 24 hours, separating doses can change the picture as much as removing one. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers Ligandrol with no sign-up.
The reported plasma half-life is about 24 hours, which is what drives how often it is redosed. Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a hormone like Ligandrol with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against Ligandrol: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
With a plasma half-life near 24 hours, once-daily dosing is the usual pattern for Ligandrol. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
With a plasma half-life near 24 hours, a single missed dose of Ligandrol usually has a smaller effect on overall exposure than an irregular pattern of missed doses does. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For Ligandrol the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
0.1 mg, 0.3 mg and 1.0 mg daily arms in the single published healthy-volunteer study. Route reported: Oral. Frequency reported: Once daily. These are amounts documented in the cited studies and labels for Ligandrol — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at Ligandrol?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.Ligandrol (LGD-4033)-Induced Liver Injury(opens PubMed in a new tab)ACG Case Rep J · 2020 · PMID 32637435 · https://pubmed.ncbi.nlm.nih.gov/32637435/
- 2.Ligandrol-induced liver injury - Case Report(opens PubMed in a new tab)Z Gastroenterol · 2023 · PMID 36257328 · https://pubmed.ncbi.nlm.nih.gov/36257328/
- 3.The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men.(opens PubMed in a new tab)The journals of gerontology. Series A, Biological sciences and medical sciences · 2013 · PMID 22459616 · https://pubmed.ncbi.nlm.nih.gov/22459616/
- 4.Effects of ligandrol as a selective androgen receptor modulator in a rat model for osteoporosis(opens PubMed in a new tab)J Bone Miner Metab · 2023 · PMID 37407738 · https://pubmed.ncbi.nlm.nih.gov/37407738/
- 5.Variation of Sequential Ligandrol (LGD-4033) Metabolite Levels in Routine Anti-Doping Urine Samples Detected with or without Other Xenobiotics(opens PubMed in a new tab)Molecules · 2023 · PMID 37764261 · https://pubmed.ncbi.nlm.nih.gov/37764261/
- 6.Ligandrol Ameliorates High-Fat Diet- and Streptozotocin-Induced Type 2 Diabetes Mellitus and Prevents Pancreatic Islets Degeneration(opens PubMed in a new tab)Assay Drug Dev Technol · 2024 · PMID 39501873 · https://pubmed.ncbi.nlm.nih.gov/39501873/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 44137686(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/44137686
- WADA Prohibited List(opens in a new tab)World Anti-Doping Agency · wada-ama.org/en/prohibited-list
Verify at
Publisher search links for Ligandrol. These are places to check the information — they are not citations, so they are not numbered.
- FDA-approved labeling (DailyMed)(publisher search, opens in a new tab)U.S. Food and Drug Administration · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- Wikipedia entry(publisher search, opens in a new tab)Wikipedia · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on Ligandrol?
Plain-text summary, safe to quote verbatim:
Ligandrol, also known as LGD-4033 or Anabolicum, is a synthetic, non-steroidal selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar anabolic properties to anabolic steroids but with reduced androgenic (masculinizing) properties. Research on Ligandrol focuses on muscle and strength, bone and joint health, and testosterone support.
Source: DoseRoutine — https://doseroutine.com/library/ligandrol
Ligandrol cheat sheet
DoseRoutine cheat sheet · Hormone
Ligandrol
Ligandrol, also known as LGD-4033 or Anabolicum, is a synthetic, non-steroidal selective androgen receptor modulator (SARM). SARMs are a class of therapeutic compounds that have similar anabolic properties to anabolic steroids but with reduced androgenic (masculinizing) properties.
Evidence
Moderate
One published human randomized trial; results not yet replicated.
Studied range
0.1 mg, 0.3 mg and 1.0 mg daily arms in the single published healthy-volunteer study
Route
Oral
Frequency studied
Once daily
Half-life
24–36 h
Storage
Room temperature, dry
Not FDA-approvedResearch chemicalNo phase 3 program has been publishedProhibited in sport by WADAMuscleBone JointTestosterone
Key references
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/ligandrol
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). Ligandrol — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ligandrol
What compounds are similar to Ligandrol?
Others in the hormone category or studied for the same goals.
Which goals is Ligandrol used for?
Other compounds studied for the same benefits as Ligandrol.
Continue exploring
See every compound DoseRoutine catalogs for these goals.